Trials / Completed
CompletedNCT00457340
Atorvastatin For The Reduction Of Ventricular Arrhythmias
Cholesterol Lowering and Arrhythmia Recurrences After Internal Defibrillator Implantation (CLARIDI)
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 220 (planned)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To assess in patients with CAD \[coronary artery disease\] and an implantable defibrillator the effect of atorvastatin 80 mg versus placebo on the first recurrence of a ventricular arrhythmia (ventricular tachycardia or ventricular fibrillation requiring ICD \[implantable cardioverter defibrillator\] intervention) within one year after randomization.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Atorvastatin 80mg |
Timeline
- Start date
- 2000-02-01
- Completion
- 2004-09-01
- First posted
- 2007-04-06
- Last updated
- 2021-02-18
Locations
10 sites across 2 countries: Belgium, Greece
Source: ClinicalTrials.gov record NCT00457340. Inclusion in this directory is not an endorsement.